{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:29:48Z","timestamp":1779204588250,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017266","name":"Gobierno de Navarra","doi-asserted-by":"publisher","award":["PDC2021-121711-100"],"award-info":[{"award-number":["PDC2021-121711-100"]}],"id":[{"id":"10.13039\/501100017266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017266","name":"Gobierno de Navarra","doi-asserted-by":"publisher","award":["PID2020-117323RB-100"],"award-info":[{"award-number":["PID2020-117323RB-100"]}],"id":[{"id":"10.13039\/501100017266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012818","name":"Comunidad de Madrid","doi-asserted-by":"publisher","award":["IND2020\/BMD-17668"],"award-info":[{"award-number":["IND2020\/BMD-17668"]}],"id":[{"id":"10.13039\/100012818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PMPTA22\/00167"],"award-info":[{"award-number":["PMPTA22\/00167"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["IFI18\/00045"],"award-info":[{"award-number":["IFI18\/00045"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020082","name":"Gobierno de Navarra Direccion General de Industria Energia y Proyectos Estrategicos S3","doi-asserted-by":"publisher","award":["PEN- 0011-1411-2023-000002"],"award-info":[{"award-number":["PEN- 0011-1411-2023-000002"]}],"id":[{"id":"10.13039\/501100020082","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019179","name":"Fundaci\u00f3n La Caixa","doi-asserted-by":"publisher","award":["HR21-00761 - IL7R-LungCan"],"award-info":[{"award-number":["HR21-00761 - IL7R-LungCan"]}],"id":[{"id":"10.13039\/501100019179","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Espa\u00f1a Ministerio de Ciencia Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["PTQ- 2019-010541"],"award-info":[{"award-number":["PTQ- 2019-010541"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001872","name":"CDTI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001872","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica de la Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["P2022\/BMD-7225 \\u2013 NEXT-GEN-CART-MAD-CM"],"award-info":[{"award-number":["P2022\/BMD-7225 \\u2013 NEXT-GEN-CART-MAD-CM"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["MCIN\/AEI\/10.13039\/501100011033"],"award-info":[{"award-number":["MCIN\/AEI\/10.13039\/501100011033"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["PDC2021-121711-100"],"award-info":[{"award-number":["PDC2021-121711-100"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["DTS20\/00089"],"award-info":[{"award-number":["DTS20\/00089"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["PID2020-117323RB-100"],"award-info":[{"award-number":["PID2020-117323RB-100"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.taap.2024.116961","type":"journal-article","created":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T11:11:49Z","timestamp":1715425909000},"page":"116961","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Pharmacokinetics and safety of LEAD-452, an EGFR-specific 4-1BB-agonistic trimerbody in non-human primates"],"prefix":"10.1016","volume":"487","author":[{"given":"Roc\u00edo","family":"Navarro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Frago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oana","family":"Hangiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ainhoa","family":"Erce-Llamazares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo","family":"L\u00e1zaro-Gorines","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel A.","family":"Morcillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 L.","family":"Rodriguez-Peralto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Compte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Alvarez-Vallina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2024.116961_bb0005","doi-asserted-by":"crossref","DOI":"10.1038\/srep28643","article-title":"Intramolecular trimerization, a novel strategy for making multispecific antibodies with controlled orientation of the antigen binding domains","author":"Alvarez-Cienfuegos","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.taap.2024.116961_bb0010","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1177\/01926233221088283","article-title":"Organ weights in relation to age and sex in cynomolgus monkeys (Macaca fascicularis)","volume":"50","author":"Amato","year":"2022","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.taap.2024.116961_bb0015","article-title":"Reference intervals and percentiles for hematologic and serum biochemical values in captive bred rhesus (Macaca mulatta) and cynomolgus macaques (Macaca fascicularis)","volume":"13","author":"Bakker","year":"2023","journal-title":"Animals (Basel)"},{"key":"10.1016\/j.taap.2024.116961_bb0020","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.yrtph.2008.04.006","article-title":"Safety evaluation to support first-in-man investigations II: toxicology studies","volume":"51","author":"Baldrick","year":"2008","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.taap.2024.116961_bb0025","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1158\/1078-0432.CCR-17-1847","article-title":"Activation of 4-1BB on liver myeloid cells triggers hepatitis via an interleukin-27\u2013dependent pathway","volume":"24","author":"Bartkowiak","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.taap.2024.116961_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/19420862.2017.1389364","article-title":"Safety testing of monoclonal antibodies in non-human primates: case studies highlighting their impact on human risk assessment","volume":"10","author":"Brennan","year":"2018","journal-title":"MAbs"},{"key":"10.1016\/j.taap.2024.116961_bb0035","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2618575","article-title":"Application of a plug-and-play immunogenicity assay in cynomolgus monkey serum for ADCs at early stages of drug development","volume":"2016","author":"Carrasco-Triguero","year":"2016","journal-title":"J Immunol Res"},{"key":"10.1016\/j.taap.2024.116961_bb0040","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1177\/0192623310368981","article-title":"Incidences and range of spontaneous findings in control cynomolgus monkeys (Macaca fascicularis) used in toxicity studies","volume":"38","author":"Chamanza","year":"2010","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.taap.2024.116961_bb0045","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.yrtph.2013.03.001","article-title":"Pharmaceutical toxicology: designing studies to reduce animal use, while maximizing human translation","volume":"66","author":"Chapman","year":"2013","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.taap.2024.116961_bb0050","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-06-741041","article-title":"Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies","volume":"131","author":"Chester","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.taap.2024.116961_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2022.105329","article-title":"Re-evaluating the need for chronic toxicity studies with therapeutic monoclonal antibodies, using a weight of evidence approach","volume":"138","author":"Chien","year":"2023","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.taap.2024.116961_bb0060","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1038\/s41467-018-07195-w","article-title":"A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity","volume":"9","author":"Compte","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.taap.2024.116961_bb0065","article-title":"Case report: an EGFR-targeted 4-1BB-agonistic trimerbody does not induce hepatotoxicity in transgenic mice with liver expression of human EGFR","volume":"11","author":"Compte","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.taap.2024.116961_bb0070","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1158\/1078-0432.CCR-20-4625","article-title":"An Fc-free EGFR-specific 4-1BB-agonistic trimerbody displays broad antitumor activity in humanized murine cancer models without toxicity","volume":"27","author":"Compte","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.taap.2024.116961_bb0075","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s40425-019-0586-0","article-title":"Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics","volume":"7","author":"Davda","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.taap.2024.116961_bb0080","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s40262-021-00987-2","article-title":"Considerations on the calculation of the human equivalent dose from toxicology studies for biologic anticancer agents","volume":"60","author":"Elmeliegy","year":"2021","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.taap.2024.116961_bb0085","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1238540","article-title":"Advancing targeted co-stimulation with antibody-fusion proteins by introducing TNF superfamily members in a single-chain format","volume":"5","author":"Fellermeier","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.taap.2024.116961_bb0090","series-title":"WHO Guidelines for the production and quality control of monoclonal antibodies and related products intended for medicinal use, TRS 1043, Annex 4Replacement of Annex 3 of WHO Technical Report Series, No. 822","year":"2024"},{"key":"10.1016\/j.taap.2024.116961_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.897991","article-title":"Utomilumab in patients with immune checkpoint inhibitor-refractory melanoma and non-small-cell lung cancer","volume":"13","author":"Hong","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.taap.2024.116961_bb0100","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.taap.2024.116961_bb0105","article-title":"PD-1\/PD-L1 checkpoint inhibitors in tumor immunotherapy","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.taap.2024.116961_bb0110","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.3390\/ani13142367","article-title":"European Union legislation for the welfare of animals used for scientific purposes: areas identified for further discussion","volume":"13","author":"Marinou","year":"2023","journal-title":"Animals"},{"key":"10.1016\/j.taap.2024.116961_bb0115","doi-asserted-by":"crossref","DOI":"10.1002\/pro.4792","article-title":"UCSF ChimeraX: tools for structure building and analysis","volume":"32","author":"Meng","year":"2023","journal-title":"Protein Sci."},{"key":"10.1016\/j.taap.2024.116961_bb0120","series-title":"A BioSafe White Paper. MAbs","article-title":"Non-human primates in the PKPD evaluation of biologics: needs and options to reduce, refine, and replace","volume":"14","author":"M\u00e9nochet","year":"2022"},{"key":"10.1016\/j.taap.2024.116961_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1258\/0023677011911345","volume":"35","author":"Morton","year":"2001","journal-title":"Lab. Anim."},{"key":"10.1016\/j.taap.2024.116961_bb0130","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic. Clin. Pharmacol."},{"key":"10.1016\/j.taap.2024.116961_bb0135","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.3747\/co.25.3840","article-title":"Current landscape of immunotherapy in the treatment of solid tumours, with future opportunities and challenges","volume":"25","author":"Nixon","year":"2018","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.taap.2024.116961_bb0140","doi-asserted-by":"crossref","first-page":"79","DOI":"10.5625\/lar.2016.32.2.79","article-title":"Reference values of clinical pathology parameters in cynomolgus monkeys (Macaca fascicularis) used in preclinical studies","volume":"32","author":"Park","year":"2016","journal-title":"Lab. Anim. Res."},{"key":"10.1016\/j.taap.2024.116961_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119523","article-title":"Protein aggregation and immunogenicity of biotherapeutics","volume":"585","author":"Pham","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.taap.2024.116961_bb0150","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1038\/s41467-019-10088-1","article-title":"Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with Fc\u03b3R affinity","volume":"10","author":"Qi","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.taap.2024.116961_bb0155","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2023.2205336","article-title":"A PD-L1\/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response","volume":"12","author":"Rubio-P\u00e9rez","year":"2023","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.taap.2024.116961_bb0160","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1228486","article-title":"Agonism of 4-1BB for immune therapy: a perspective on possibilities and complications","volume":"14","author":"Salek-Ardakani","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.taap.2024.116961_bb0165","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1158\/1078-0432.CCR-16-1272","article-title":"Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody","volume":"23","author":"Segal","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.taap.2024.116961_bb0170","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1158\/1078-0432.CCR-17-1922","article-title":"Phase I study of single-agent utomilumab (PF-05082566), a 4-1BB\/CD137 agonist, in patients with advanced cancer","volume":"24","author":"Segal","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.taap.2024.116961_bb0175","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1190379","article-title":"Cytokine release syndrome and cancer immunotherapies \u2013 historical challenges and promising futures","volume":"14","author":"Shah","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.taap.2024.116961_bb0180","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1158\/2159-8290.CD-20-1680","article-title":"The next decade of immune checkpoint therapy","volume":"11","author":"Sharma","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.taap.2024.116961_bb0185","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1208\/s12248-019-0304-3","article-title":"Pharmacokinetic properties of humanized IgG1 and IgG4 antibodies in preclinical species: translational evaluation","volume":"21","author":"Tabrizi","year":"2019","journal-title":"AAPS J."},{"key":"10.1016\/j.taap.2024.116961_bb0190","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/ajh.25757","article-title":"Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma","volume":"95","author":"Timmerman","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.taap.2024.116961_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2012.04.040","article-title":"Immunogenicity of protein aggregates\u2013concerns and realities","volume":"431","author":"Wang","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.taap.2024.116961_bb0200","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004225","article-title":"Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology","volume":"10","author":"Zhou","year":"2022","journal-title":"J. Immunother. Cancer"}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X24001595?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X24001595?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:11:32Z","timestamp":1777457492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X24001595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":40,"alternative-id":["S0041008X24001595"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2024.116961","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics and safety of LEAD-452, an EGFR-specific 4-1BB-agonistic trimerbody in non-human primates","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2024.116961","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116961"}}